Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23)
Note: clicking this link will take you to an external website.
Site-Specific Conjugation of Cell Wall Polyrhamnose to Protein SpyAD Envisioning a Safe Universal Group A Streptococcal Vaccine
A Porphyromonas gingivalis Capsule-Conjugate Vaccine Protects From Experimental Oral Bone Loss
Immunization with cell-free-generated vaccine protects from Porphyromonas gingivalis-induced alveolar bone loss
Effcient production of immunologically active Shigella invasion plasmid antigens IpaB and IpaH using a cell-free expression system
SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains
Repertoire of Naturally Acquired Maternal Antibodies Transferred to Infants for Protection Against Shigellosis
Site specific antigen adjuvant conjugation using cell free protein synthesis enhances antigen presentation and CD8+ T cell response
Copyright © 2022 Vaxcyte, Inc. All Rights Reserved.